huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

Stomach Neoplasms Clinical Trial

Official title:

A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00620607
• Other study ID #: IMGN 102
• Status: Withdrawn
• Phase: Phase 2
• First received: February 7, 2008
• Last updated: August 25, 2015
• Start date: May 2007
• Est. completion date: September 2010

Study information

• Verified date: April 2009
• Source: ImmunoGen, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must understand and voluntarily sign an informed consent.

• Patients must have histological documentation of metastatic or locally advanced (American Joint Committee on Cancer Staging System: Stages IIIA, IIIB, and IV) gastric or gastroesophageal junction adenocarcinoma.

• Patients must have ECOG performance status < 1.

• Patients must be at least 18 years of age.

• Patients who have been treated with only one prior chemotherapy regimen and who have documented disease progression.

• Patients must have confirmation of CanAg expression performed prior to enrollment by immunohistochemical assessment for CanAg on archived biopsy samples.

• Patients must have measurable disease with at least one lesion that can be accurately measured by Response Evaluation Criteria in Solid Tumors (RECIST). The lesion size must be at least 20 mm by conventional radiological techniques or at least 10 mm by spiral CT scan. Disease in an irradiated field as the only site of measurable disease is acceptable if there has been a clear progression of the lesion.

• Patients with reproductive potential must agree to use an effective contraceptive method during the study and for 30 days after receiving the last dose of study drug.

• Women of childbearing potential (WCBP) must have a negative urine or serum pregnancy test within one week prior to enrollment in the study.

• Patients must have any chemotherapy, immunotherapy, hormonal therapy, radiotherapy for cancer or surgery (except for minor surgical procedures) completed at least 3 weeks before starting study medication.

• Patients must have resolution of all clinically significant toxic effects (excluding alopecia) of any prior treatments including surgery, radiotherapy, hormone therapy, immunotherapy, targeted non-cytotoxic therapy, or chemotherapy to grade = 1 by NCI CTCAE v. 3.0 unless otherwise specified in the inclusion laboratory values.

• Patients must have adequate organ function including:

1. Hematopoietic:

i. Absolute neutrophil count > 1,500/mm3. ii. Platelet count > 100,000/mm3. iii. Hemoglobin > 9 g/dL (transfusion allowed).

2. Renal:

i. Serum creatinine = 1.5 x the upper limit of normal (ULN) ii. Calculated creatinine clearance > 60 mL/min/1.73m2.

3. Hepatic:

i. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) = 2.5 x ULN ii. Total bilirubin = 1.5 x ULN

Exclusion Criteria:

• Pregnant or lactating women. Women of childbearing potential (WCBP) must have a negative urine or blood test for pregnancy before first treatment.

• Known hypersensitivity to previous monoclonal antibody therapy or maytansinoids.

• Active and uncontrolled infection.

• Known history hepatitis B or C, HIV, or history of alcoholic liver disease.

• Patients with any serious medical or psychiatric disorder that would interfere with patient safety or informed consent.

• Patients with peripheral neuropathy grade 2 or greater.

• Patients with known leptomeningeal disease or progressive brain metastasis. Routine screening with CNS imaging studies (CT or MRI) is required only if clinically indicated.

• Patients with concomitant malignancies or previous malignancies with less than a 2 year disease free interval at the time of dosing. Patients with adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or Stage A low-grade prostate cancer may enroll irrespective of the time of diagnosis.

• Patients who are receiving concomitant chemotherapy, immunotherapy, radiotherapy, or investigational therapy. Radiotherapy for palliation of related bone metastases is permitted upon the agreement between the investigator and the ImmunoGen Medical Monitor and as long as radiation does not involve target lesions that are followed for drug treatment response evaluation.

• Patients with any severe concurrent disease or condition, which in the judgment of the Investigator, would make the patient inappropriate for study participation. The disease or condition include, but are not limited to, one or more of the following: bleeding diathesis, uncontrolled chronic kidney or liver disease, uncontrolled diabetes, history of cardiac disease, myocardial infarction within the past 6 months, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and uncontrolled hypertension.

• Patients who must use contact lenses and cannot discontinue use of their contact lenses during the course of the clinical study. Patients must discontinue use of contact lenses prior to receiving study drug.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Metastatic or Local Advanced GE Junction Cancer
• Metastatic or Locally Advanced Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• huC242-DM4
dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks

Locations

Country	Name	City	State
United States	UAB Comprehensive Cancer Center	Birmingham	Alabama
United States	U.T. M.D. Anderson Cancer Center	Houston	Texas
United States	Vanderbilt-Ingram Cancer Center	Nashville	Tennessee
United States	South Texas Accelerated Research Therapeutics	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
ImmunoGen, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	response rate		year	No
Secondary	duration of response		as necessary	No
Secondary	progression free survival		as necessary	No
Secondary	safety and tolerability		while on study	Yes
Secondary	Pharmacokinetic (PK) assessment		while on study	Yes
Secondary	effect of huC242-DM4 on tumor uptake of FDG		while on study	No